Jennifer Dong

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 477 citations · Full text

Obesity, Metabolic Syndrome, Long-acting Fgf21 Molecule +12

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

Jennifer Dong, David H. Salinger, Christopher J. Endres et al. · Clinical Pharmacokinetics · 2011 · 153 citations

Translational Medicine, Medicine, Biostatistics +6

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 136 citations

Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study

Jennifer Dong, Michelle I. Rossulek, Veena Somayaji et al. · British Journal of Clinical Pharmacology · 2015 · 98 citations · Full text

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series

Sudha S. Shankar, Adrian Vella, Ralph Raymond et al. · Diabetes Care · 2016 · 73 citations · Full text